Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: HYTRIN

« Back to Dashboard
Hytrin is a drug marketed by Abbott and is included in two NDAs.

The generic ingredient in HYTRIN is terazosin hydrochloride. There are twenty-four drug master file entries for this compound. Additional details are available on the terazosin hydrochloride profile page.

Summary for Tradename: HYTRIN


Clinical Trials for: HYTRIN

Pilot Study of Terazosin in Treatment of Antidepressant Induced Excessive Sweating
Status: Completed Condition: Antidepressant Induced Excessive Sweating

FLOMAX® Versus HYTRIN® in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia
Status: Completed Condition: Prostatic Hyperplasia

A Pharmacodynamic Study of Dapoxetine Concomitantly Administered in Participants Taking Terazosin
Status: Completed Condition: Ejaculation

Effect of Amlodipine Monotherapy or Combined With Terazosin on Lower Urinary Tract Symptoms and Hypertension
Status: Completed Condition: Lower Urinary Tract Symptoms; Hypertension

Excessive Sweating Caused by Antidepressants: Measurement and Treatment With Terazosin
Status: Completed Condition: Hyperhidrosis

The Effect of Terazosin and Tolterodine on Ureteral Stent Related Symptoms
Status: Completed Condition: Disorder of Urinary Stent

Randomized Trial Comparing Terazosin 5 mg Daily and Doxazosin GITS 4 mg Daily for Trial Without Catheter in Acute Urinary Retention With Long Term Follow up
Status: Terminated Condition: Prostatic Hyperplasia; Urinary Retention

Diesel Exhaust and Vascular Function
Status: Recruiting Condition: Cardiovascular Effects

Alpha-blocker Plus Diuretic Combination Therapy as Second-line Treatment for Nocturia in Men
Status: Completed Condition: Nocturia

Clinical Progression and Costs in Benign Prostatic Hyperplasia Patients Treated With Early Versus Delayed Combination Therapy
Status: Completed Condition: Benign Prostatic Hyperplasia

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
terazosin hydrochloride
CAPSULE;ORAL020347-001Dec 14, 1994DISCNNo<disabled><disabled>
terazosin hydrochloride
TABLET;ORAL019057-003Aug 7, 1987DISCNNo<disabled><disabled>
terazosin hydrochloride
CAPSULE;ORAL020347-004Dec 14, 1994DISCNNo<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn